List view / Grid view
The in vivo, one-time gene editing therapy has potential to…
The in vivo, one-time gene editing therapy has potential to transform outcomes for alpha-1 antitrypsin deficiency (AATD).
The European Commission (EC) approved Rinvoq® as the first JAK…
The European Commission (EC) approved Rinvoq® as the first JAK inhibitor in Europe for the treatment of moderate to severe atopic dermatitis.
Two Phase III trials have shown that two doses of…
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
Phase 3 clinical program for upadacitinib in atopic dermatitis, the…
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018...
